Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies (Tables)

v3.26.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2026
Summary of Significant Accounting Policies  
Schedule of significant expense categories

Three Months Ended

March 31, 

March 31, 

2026

  ​ ​ ​

2025

Operating expenses:

Clinical

$

1,809,420

$

1,817,232

Chemical, manufacturing and controls

265,725

135,122

Research and preclinical

(5,634)

24,134

Regulatory

14,662

21,658

Other research and development costs

585,606

438,852

Total research and development

2,669,779

2,436,998

General and administrative expenses

2,406,587

1,992,928

Total operating expenses

$

5,076,366

$

4,429,926

Sublease income

(19,455)

Loss on debt conversion with related party

6,134,120

Interest (income)/expense, net

(77,350)

147,090

Exchange loss, net

 

5,860

 

23,274

Net loss before income taxes

$

4,985,421

$

10,734,410